Clinical significance
Colorectal cancer is one of the most commonly diagnosed, but nothing
has been approved for the chemoprevention in high-risk patients.
Polar analogs of conventional phosphodiesterase 5 inhibitors are
attractive agents for colon cancer prevention because they are
gut-targeted and are expected to have reduced side-effects and
drug-drug interactions.